

Use of this content is subject to the Terms and Conditions

CLINICAL REVIEW: Thyrotoxic Periodic Paralysis: A Diagnostic Challenge

[Journal of Clinical Endocrinology and Metabolism](#) - Volume 91, Issue 7 (July 2006) - Copyright © 2006 The Endocrine Society

2490

Special Features

CLINICAL REVIEW: Thyrotoxic Periodic Paralysis: A Diagnostic Challenge

Annie W. C. Kung ¹

¹ Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China

Received February 16, 2006.

Accepted April 4, 2006.

Address all correspondence and requests for reprints to: Annie W. C. Kung, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. E-mail: awckung@hkucc.hku.hk.

Copyright © 2006 by The Endocrine Society

F

Abbreviations:

ECG
Electrocardiographic
EMG
electromyogram
FHPP
familial hypokalemic periodic paralysis
HLA
human leukocyte antigen
Na/K-ATPase
sodium-potassium-adenosine triphosphatase
SNP
single-nucleotide polymorphism
TPP
thyrotoxic periodic paralysis
TRE
thyroid hormone-responsive element

Context: The aim of this article was to review the clinical presentation, pathogenesis, and management of thyrotoxic periodic paralysis (TPP).

Evidence Acquisition: A MEDLINE search was conducted for articles published

during the last 40 yr based on the key words thyrotoxic periodic paralysis and hypokalemic periodic paralysis. A total of 281 primary articles and 168 references of the retrieved articles were also reviewed.

Evidence Synthesis: TPP is a common complication of hyperthyroidism in Asian men but is increasingly seen in Western countries. Hypokalemia and muscle paralysis results from a sudden intracellular shift of potassium and is not due to potassium deficiency. Clinical features of hyperthyroidism in patients with TPP may be subtle. Immediate potassium supplementation prevents serious cardiopulmonary complications and may hasten the recovery of muscle weakness. Nonselective β -adrenergic blockers can ameliorate and prevent recurrence of the paralytic attacks. This episodic paralysis will remit with definitive control of hyperthyroidism. Increased sodium-potassium ATPase pump activity and enhanced insulin response in patients with TPP is postulated to contribute to the hypokalemia. The genetic predisposition for TPP is not entirely clear. Association of polymorphisms of the calcium channel α 1-subunit gene with TPP has been noted.

Conclusions: Due to population mobility, TPP is increasingly common in Western countries. Early diagnosis and prompt treatment prevent life-threatening complications associated with hypokalemia and muscle weakness. Assaying of thyroid function in patients with hypokalemic paralysis distinguishes TPP from other forms of hypokalemic periodic paralysis. (*J Clin Endocrinol Metab* 91: 2490–2495, 2006)

THYROTOXIC PERIODIC PARALYSIS (TPP) is an alarming and potentially lethal complication of hyperthyroidism characterized by muscle paralysis and hypokalemia due to a massive intracellular shift of potassium. This condition mainly affects male patients of Asian descent. Many affected patients do not have obvious symptoms and signs of hyperthyroidism. Because the condition is rare in Caucasians, it is frequently overlooked and misdiagnosed on presentation. With increasing population mobility and admixture, TPP as the presenting feature of hyperthyroidism is more common in Western countries. Immediate therapy with potassium supplementation and β -adrenergic blockers can prevent serious cardiopulmonary complications and may hasten recovery of the periodic paralysis. Effective control of hyperthyroidism is indicated to prevent the recurrence of paralysis.

Epidemiology

TPP is a well-known complication of thyrotoxicosis in Asian populations, including Chinese, Japanese, Vietnamese, Filipino, and Koreans. The overall incidence of TPP in Chinese and Japanese thyrotoxic patients is 1.8 and 1.9%, respectively [1] [2] . The incidence is largely unknown in the West. In North America, the incidence rate of TPP was reported to be around 0.1–0.2% in thyrotoxic patients [3] [4] . Sporadic cases of TPP have also been reported in other non-Asian populations such as Caucasians, Afro-Americans, American Indians, and Hispanics. The American Indians are thought to be at a higher risk of TPP [5] because there is evidence that their ancestors originated in Asia and migrated to North America between 11,000 and 23,000 yr ago [6] .

Despite a much higher incidence of thyrotoxicosis in women, TPP predominantly affects males. In the Chinese, TPP occurs in 13% of male and 0.17% of female thyrotoxic patients, in a series published in 1967 [1] , whereas in the Japanese, the incidence was 8.67 among male and 0.4% among female thyrotoxic patients in 1957 [2] . Overall, the

male to female ratio ranges from 17:1 to 70:1 [1] [2] [7] [8] . Interestingly, a decline in the incidence of TPP has been reported in Japan, with the figures being 4.3% among male and 0.04% among female thyrotoxic patients in 1991 [9] .

The number of TPP cases reported in Western countries has increased recently. A computer search revealed nine review papers and 72 case reports (41 Asians and 31 non-Asians) published between 1986 and 1995, whereas in 1996–2005, a total of 25 review papers and 67 case reports (24 Asians and 43 non-Asians) were published, suggesting that TPP is no longer an unusual condition in the Western medical arena.

Clinical Presentation

Patients are usually young adult males 20–40 yr of age, although occurrence of TPP in adolescents has also been

First Published Online April 11, 2006

2491

reported [10] [11] . The attack is characterized by recurrent, transient episodes of muscle weakness that range from mild weakness to complete flaccid paralysis (Table 1). The proximal muscles are affected more severely than the distal muscles. Attacks usually first involve the lower limbs and progress to the girdle muscles and subsequently the upper limbs. Sensory function is not affected. The muscles affected may be asymmetrical. Although patients can present with tetraparesis that resembles other conditions such as Gullain-Barré syndrome, transverse myelitis, and acute spinal cord compression or hysteria, bowel and bladder function are never affected. Respiratory muscles are seldom involved but total paralysis of respiratory, bulbar, and ocular muscles has been reported in a severe attack [12] [13] [14] . Patients may experience recurrent episodes of weakness that last from a few hours up to 72 h, with complete recovery in between the attacks. There may also be prodromal symptoms of aches, cramps, and stiffness of the affected muscles. In the majority of patients, deep tendon reflexes are markedly diminished or absent, although some patients may have brisk or normal jerks, even during paralysis [15] .

Patients with TPP usually experience the attack a few hours after a heavy meal or in the early morning upon waking: more than two thirds of patients present to the emergency department between 2100 and 0900 h. Such timing of presentation led the condition to be initially described as nocturnal paralysis or night palsy [16] . Patients may give a history of similar but milder attacks before presentation. Attacks are commonly precipitated by ingestion of carbohydrate-rich meals or sweet snacks, alcohol, or strenuous exercise. In these patients the paralysis can be induced by a high glucose load, insulin infusion, and exercise test. The weakness does not occur during exercise but during the resting period after exercise and may be aborted by resumption of the exercise. In subtropical regions, a seasonal variation is observed that is probably related to increase outdoor exercise or consumption of sweet drinks during summer [1] [8] . TPP occurs only in the presence of hyperthyroidism and is abolished when thyroid hormone levels are normalized. Likewise the paralysis can be induced only when the patient is thyrotoxic, not euthyroid. The attacks of weakness are similar to those of familial hypokalemic periodic paralysis (FHPP) except for the presence of hyperthyroidism (Table 2). Nonetheless, whereas FHPP is an autosomal dominant condition

TABLE 1 -- Clinical features of TPP

Feature

Adult young men

Sporadic

Recurrent acute paralysis with complete recovery

Limb > trunk involvement

Precipitated by heavy carbohydrate load, high-salt diet, alcohol, exertion

Family history of hyperthyroidism

Clinical features of hyperthyroidism

Hypokalemia

Normal acid-base balance

Low potassium excretion rate

Low phosphate excretion

EMG: low-amplitude compound muscle action potential with no change after epinephrine

that affects mainly Caucasians [17] [18] , TPP is a sporadic disease found mainly in Asian males, and the familial trait is rare [3] [19] [20] .

Biochemical Features

Hyperthyroidism

Biochemical hyperthyroidism distinguishes patients with TPP from FHPP. Most patients with TPP have only mildly elevated serum thyroid hormone levels: a previous study reported only 10% of patients with mild thyrotoxic symptoms [8] . Indeed, the hyperthyroidism may even be clinically silent [4] . The subtlety of the features of hyperthyroidism together with the rarity of this condition makes TPP a difficult condition to diagnose at presentation.

The majority of cases of hyperthyroidism associated with TPP are due to Graves' disease, although other conditions including thyroiditis [7] , toxic nodular goiter [21] , toxic adenoma [4] , TSH-secreting pituitary tumor [22] , ingestion of T₄ [23] , and inadvertent iodine excess [24] have also been implicated. TPP may be the presenting feature of Graves' disease, or present during relapse or after radioactive iodine therapy [25] .

Electrolytes

The hallmark of TPP is hypokalemia. The presenting serum potassium level is usually less than 3.0 mmol/liter and can be as low as 1.1 mmol/liter. Occasionally if the patient is at the recovery stage of the paralysis, serum potassium can be normal. Hypokalemia occurs due to a massive shift of potassium into the cells rather than net loss from the body. It is not associated with urinary potassium loss because the urinary potassium excretion is normal or low, and the blood acid-base balance is normal [26] [27] . Similarly, there is no excessive fecal loss of potassium. The degree of hypokalemia is correlated to the severity of paralysis but not to the clinical features of thyrotoxicosis or thyroid hormone levels. Fatal and life-threatening ventricular arrhythmia associated with hypokalemia has been reported [28] [29] [30] .

In addition to hypokalemia, there may be hypophosphatemia and hypomagnesemia. Mild to moderate hypophosphatemia in the range of 0.36–0.77 mmol/liter has been reported in two thirds of cases in one series [31] . Serum phosphate level returns to normal without supplementation when the patient recovers from the weakness. This is confirmed by the

occurrence of rebound hyperphosphatemia after recovery from paralysis in patients prescribed phosphate supplementation [27] [32]. The hypophosphatemia is likely due to intracellular shift that accompanies the potassium transport. Similarly, serum magnesium level is low or low normal but returns to normal spontaneously when the patient recovers from the paralytic attack [31]. The hypomagnesemia is also due to intracellular shift, likely secondary to endogenous catecholamines released during stress rather than due to depletion of body stores [33].

Serum creatine phosphokinase of muscle origin is elevated in about two thirds of patients, particularly among those whose attacks are precipitated by exercise. The complication of rhabdomyolysis may occur in a severe attack [31].

2492

TABLE 2 -- Distinguishing features between TPP and FHPP

	TPP	FHPP
Age (yr)	20–40	<20
Sex distribution	Predominantly male	Equal
Heredity	Sporadic	Autosomal dominant
Ethnicity	Asian, American Indian/Hispanic, Caucasian	Caucasian, Asian
Family history	History of thyrotoxicosis	History with hypokalemic paralysis
Clinical features of hyperthyroidism	Yes	No
Genetic predisposition	Associated with SNPs of Ca _v 1.1 (-476A→G, intron 2 nt 57G→A, intron 26 nt 67A→G)	Mutations of Ca _v 1.1 (R5258H, R1239H, R1239G), Na _v 1.4 (R669H, R672G, R672H), K _v 3.4 (R83H)

Electrodiagnostic studies

Electromyogram (EMG) performed during spontaneous weakness typically reveals myopathic changes with reduced amplitude of compound muscle action potentials [34]. There is no notable change in the amplitude on epinephrine stimulation. Nerve conduction studies are normal with no peripheral nerve involvement. Similar to FHPP, exercise can induce weakness in patients with TPP, and an exercise test can reproduce the EMG abnormalities during paralysis. These impaired muscle responses improve when the patient becomes euthyroid.

TPP patients have significantly more electrocardiographic (ECG) abnormalities than patients with hypokalemic periodic paralysis due to other causes. Apart from serious ventricular arrhythmias and ECG changes associated with hypokalemia, other ECG abnormalities include rapid heart rate, high QRS voltage, and first-degree atrioventricular block [35].

Pathogenesis

The pathogenesis of TPP remains unclear. Hypokalemia is the consequence of a rapid

and massive shift of potassium from the extracellular into the intracellular compartment, mainly into the muscles. This is believed to be related to increased sodium-potassium-adenosine triphosphatase (Na/K-ATPase) pump activity (Fig. 1). Potassium flux and




Figure 1. Mechanisms for acute muscle weakness in thyrotoxic periodic paralysis.

sodium transport as well as Na/K-ATPase pump activity have been evaluated in patients with TPP. Studies were nonetheless performed in peripheral tissues such as red blood cells, leukocytes, and platelets because of the inherent difficulties in measuring ion transport in intact skeletal muscles during TPP. Overall, the data revealed an increased number as well as activity of the Na/K-ATPase pump in patients with thyrotoxicosis: patients with TPP had significantly higher pump activity than thyrotoxic patients without TPP [36] [37] [38]. When thyrotoxicosis was controlled, Na/K-ATPase activity returned to a level similar to that of healthy controls.

Thyroid hormones can increase Na/K-ATPase activity in skeletal muscle, liver, and kidney to induce an influx of potassium into the intracellular space [39] [40] [41] [42]. Among the various Na/K-ATPase subunits, the α 1-, α 2-, β 1-, β 2-, and β 4-subunits are expressed in skeletal muscles [43] [44]. Thyroid hormone-responsive elements (TREs) are present in the upstream region of these five genes, and thyroid hormones has been shown to increase Na/K-ATPase activity via both transcriptional and posttranscriptional mechanisms [45] [46]. Apart from direct stimulation by thyroid hormones, catecholamine can also increase Na/K-ATPase activity in skeletal muscle [47]. The enhanced β -adrenergic response in thyrotoxicosis further increases Na/K-ATPase activity and may explain why nonselective β -adrenergic blockers can abort or prevent paralytic attacks.

In addition to an increased adrenergic response, patients with TPP have an exaggerated insulin response during oral glucose challenge, compared with thyrotoxic patients without TPP [48] [49]. Insulin-response sequences are present in the upstream region of Na/K-ATPase genes, and insulin has been shown to stimulate Na/K-ATPase activity [50]. Hence, insulin can play a permissive role for the potassium shift in patients with TPP. The hyperinsulinemic response may explain the association of TPP with carbohydrate-rich

meals and sweet snacks. Exercise releases potassium from the skeletal muscles, whereas rest promotes influx of potassium. This explains why paralytic attacks occur only during recovery from exercise and resumption of exercise can abort an attack [3] .

Overall, it appears that patients with TPP have an underlying predisposition for activation of Na/K-ATPase activity, either directly by thyroid hormone or indirectly via adrenergic stimulation, insulin, or exercise. To determine whether this predisposition is genetically associated, a number of studies have addressed different candidate genes. The human leukocyte antigen (HLA) B46, DR9, and DQB1 * 0303

2493

have been reported to be present at a higher prevalence among Hong Kong Chinese TPP patients, whereas HLA A2, Bw22, AW19, B17, and DRW8 are reported to be associated in Singapore Chinese and Japanese, respectively [51] [52] [53] . However, it is uncertain whether these HLA genes are independently related to TPP because these HLA associations are also observed with Graves' disease *per se*.

In view of similarities between TPP and FHPP, the role of genes associated with FHPP has also been examined in patients with TPP (Table 2). The L-type calcium channel α 1-subunit Ca_v 1.1, also called the voltage-dependent calcium channel or dihydropyridine-sensitive L-type calcium channel receptor, which is associated with FHPP-1, was studied. None of the few mutation hot spots associated with FHPP was present in Asian or non-Asian patients with TPP [54] [55] . However, certain single-nucleotide polymorphisms (SNPs) of Ca_v 1.1, including nucleotide (nt) – 476, intron 2 nt 57, and intron 26 nt 67, were associated with TPP in southern Chinese [55] . The location of these SNPs lies at or close to the TRE of the gene, and it is likely that they affect the binding affinity of TRE and modulate the stimulation of thyroid hormone on the Ca_v 1.1 gene.

Similarly, mutations in other genes that encode for skeletal muscle ionic channels have also been examined. One TPP patient of Portuguese descent has been found to carry an R83H mutation in the K_v 3.4 gene that encodes for voltage-gated potassium channel [56] . In addition the R672G mutation of the voltage-gated sodium channel Na_v 1.4 that is associated with FHPP-2 is reported in one pediatric Caucasian patient with thyrotoxicosis and paralysis [57] . Interestingly, family members of these two probands also carry similar mutations and have hypokalemic paralysis without thyrotoxicosis. The authors postulated that there may be overlap of genetic predisposition between FHPP and TPP. However, these two mutations are not found in any of the 97 southern Chinese TPP patients studied [55] , or in other series of Asian TPP patients [58] [59] .

Because patients with TPP have increased Na/K-ATPase activity, the genes coding for the α 1-, α 2-, β 1-, β 2-, and β 4-subunits of Na/K-ATPase were examined. No mutations were identified in the 5' upstream region and the coding region of these five genes in southern Chinese patients with TPP [59] . Also, no association between the SNPs of these five genes and TPP could be detected [60] . Similarly, polymorphism in the β 2-adrenergic receptor gene is not associated with TPP in Korean patients [61] . Thus, whether TPP patients truly have a genetic predisposition to activation of the Na/ K-ATPase genes remains to be elucidated.

Treatment

During periodic paralysis and marked hypokalemia, immediate supplementation with potassium chloride (KCl) is warranted to prevent major cardiopulmonary complications.

KCl is given iv or orally or both (Table 3). The dose of KCl required varies between 40 and 200 mmol. Recovery time was significantly shorter in those given iv KCl infusion than those given saline infusion alone [62]. However, other studies have shown a lack of correlation between the dose of KCl given with the initial serum potassium level and the recovery

TABLE 3 -- Treatment of TPP

Treatment type
Emergency therapy
Potassium replacement
KCl 10 mEq/h iv and/or KCl 2 g every 2 h, orally
Monitor serum K ⁺ level, avoid rebound hyperkalemia
Propranolol 3–4 mg/kg, orally
Prevention of recurrent attacks
Avoid precipitating factors (heavy carbohydrate meals, high salt, alcohol, undue exertion) until euthyroidism is achieved
Propranolol 20–80 mg every 8 h, orally
Determine the cause of TPP
Definitive therapy of hyperthyroidism with antithyroid drugs/thyroidectomy/radioiodine

of muscle weakness [8] [31]. Excessive potassium replacement may result in rebound hyperkalemia during recovery of the paralysis when potassium is shifted back into the intravascular compartment. It was reported that 40% of patients given iv KCl at a rate of 10 mmol/h developed rebound hyperkalemia greater than 5.5 mmol/liter [62]. Thus KCl supplementation should be given at a slow rate unless there are cardiopulmonary complications. Use of potassium supplements is not useful for prophylaxis against further paralytic attacks and should not be given to patients between attacks.

Oral or iv propranolol, a nonspecific β -adrenergic blocker, has also been proposed as an alternative treatment to ameliorate the paralysis without rebound hyperkalemia and raise the serum levels of potassium and phosphate. Three case reports showed that iv propranolol rapidly reversed the paralysis in patients with TPP who failed to respond to potassium replacement [63] [64] [65]. Similarly, high-dose oral propranolol (3–4 mg/kg orally) alone has been reported to rapidly abort the paralysis [66]. Propranolol, but not the selective β_1 -blocker metoprolol, also effectively prevented recurrence of paralytic attacks or inhibited paralysis induced by a carbohydrate load. At a dose of 40 mg four times a day, propranolol prevented paralysis in carbohydrate-induced TPP in about two thirds of cases by inhibiting the activity of Na/K-ATPase [67]. In view of the small number of case reports on the use of β -blockers alone, more controlled studies are needed to determine their efficacy, compared with potassium supplementation in the emergency treatment of TPP.

Because TPP does not recur once the patient is euthyroid, adequate control of hyperthyroidism is the mainstay of therapy. The cause for the hyperthyroidism should be identified. Definitive treatment with radioactive iodine or thyroidectomy should be given to patients with hyperthyroidism due to Graves' disease, multinodular goiter, or toxic adenoma. Patients should avoid precipitating factors including heavy carbohydrate intake, high-salt diet, alcohol ingestion, and undue exertion until thyrotoxicosis is under control. The use of nonselective β -blockers is important during early treatment with antithyroid drugs or after radioactive iodine when a euthyroid status is not yet achieved. Regular potassium supplementation as prophylaxis against further paralysis when the patient has a normal serum potassium level is ineffective. Acetazolamide and T₄, which have been reported to reduce the frequency of paralytic attacks in FHPP and

other forms of hypokalemic periodic paralysis, may worsen the attacks in TPP [68] [69] and should be avoided.

Conclusion

TPP is a rare condition in non-Asians, and the diagnosis at initial presentation is often delayed because of the subtleness of the clinical features of thyrotoxicosis and the similarities of the paralysis with other more common conditions. With population mobility and admixture, TPP is becoming more common in Western countries. Early diagnosis prevents serious cardiopulmonary complications. TPP is a curable disorder that resolves when a euthyroid status is achieved.

References

1. **McFadzean AJS, Yeung R** 1967 Periodic paralysis complicating thyrotoxicosis in Chinese. *Br Med J* 1:451–455 Citation
2. **Okinaka S, Shizume K, Lino S, Watanabe A, Irie M, Noguchi A, Kuma S, Kuma K, Ito T** 1957 The association of periodic paralysis and hyperthyroidism in Japan. *J Clin Endocrinol Metab* 17:1454–1459
3. **Ober KP** 1992 Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. *Medicine* 71:109–120 Abstract
4. **Kelley DE, Gharib H, Kennedy FP, Duda RJ, McManis MB** 1989 Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. *Arch Intern Med* 149:2597–2600 Abstract
5. **Layzer RB** 1990 Neuromuscular manifestation of endocrine disease. In: Becker KL, ed. *Principles and practice of endocrinology and metabolism*. Philadelphia: JB Lippincott; 1536
6. **Wendorf M, Goldfine ID** 1991 Archaeology of NIDDM. Excavation of the "thrifty" genotype. *Diabetes* 40:161–165 Abstract
7. **Tinker TD, Vannatta JB** 1987 Thyrotoxic hypokalemic periodic paralysis: report of four cases and review of the literature. *J Okla State Med Assoc* 80:76–83 (Review) Citation
8. **Ko GTC, Chow CC, Yeung VTF, Chan HHL, Li JKY, Cockram CS** 1996 Thyrotoxic periodic paralysis in a Chinese population. *Q J Med* 89:463–468
9. **Shizume K, Shishiba Y, Kuma K, Noguchi S, Tajiri J, Ito K, Noh JY** 1992 Comparison of the incidence of association of periodic paralysis and hyperthyroidism in Japan in 1957 and 1991. *Endocrinol Jpn* 39:315–318 Abstract
10. **Wong GW, Leung TF, Lo AF, Ahuja AT, Cheng PS** 2000 Thyrotoxic periodic paralysis in a 14-year-old boy. *Eur J Pediatr* 159:934 Citation
11. **Schalin-Jantti C, Laine T, Valli-Jaakola K, Lonnqvist T, Kontula K, Valimaki MJ** 2005 Manifestation, management and molecular analysis of candidate genes in two rare cases of thyrotoxic hypokalemic periodic paralysis. *Horm Res* 63:139–144 Abstract
12. **Liu YC, Tsai WS, Chau T, Lin SH** 2004 Acute hypercapnic respiratory failure due to thyrotoxic periodic

paralysis. *Am J Med Sci* 327:264–267 Abstract

13. **Ahlawat SK, Sachdev A** 1999 Hypokalemic paralysis. *Postgrad Med J* 75: 193–197 Abstract
14. **Crane MG** 1960 Periodic paralysis associated with hyperthyroidism. *Calif Med* 92:285–288
15. **Schutta HS, Armitage JL** 1969 Thyrotoxic hypokalemic periodic paralysis. *J Neuropath Exp Neurol* 28:321–336
16. **Talbott JH** 1941 Periodic paralysis. *Medicine* 20:85–142
17. **Lapie P, Lory P, Fontaine B** 1997 Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel. *Neuromuscul Disord* 7:234–240 (Review) Abstract
18. **Links TP, Smit AJ, Molenaar WM, Zwarts MJ, Oosterhuis HJ** 1994 Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. *J Neurol Sci* 122:33–43 Abstract
19. **Papadopoulos KI, Diep T, Cleland B, Lunn NW** 1997 Thyrotoxic periodic paralysis: report of three cases and review of the literature. *J Intern Med* 241:521–524 Abstract
20. **Kung AWC** 2002 Thyrotoxic periodic paralysis. In: Wass JAH, Shalet SM, eds. *Oxford textbook of endocrinology and diabetes*. Oxford, UK: Oxford University Press; 427–429
21. **Norris Jr FH, Clark EC, Biglieri EG** 1972 Studies in thyrotoxic periodic paralysis. Metabolic and ultrastructural studies. *Arch Neurol Sci* 13:431–432
22. **Hsu FS, Tsai WS, Chau T, Chen HH, Chen YC, Lin SH** 2003 Thyrotropin-secreting pituitary adenoma presenting as hypokalemic periodic paralysis. *Am J Med Sci* 325:48–50 Abstract
23. **Okiihiro MM, Nordyke RA** 1966 Hypokalemic periodic paralysis: experimental precipitation with sodium liothyronine. *JAMA* 198:949–951 Citation
24. **Tran HA** 2005 Inadvertent iodine excess causing thyrotoxic hypokalemic periodic paralysis. *Arch Intern Med* 165:2536 Citation
25. **Akar S, Comlekci A, Biklik M, Onen F, Sari I, Gurler O, Bekis R, Akkoc N** 2005 Thyrotoxic periodic paralysis in a Turkish male: the recurrence of the attack after radioiodine treatment. *Endocr J* 52:149–151 Abstract
26. **Nora NA, Berns AS** 1989 Hypokalemic, hypophosphatemic thyrotoxic periodic paralysis. *AM J Kidney Dis* 13:247–249
27. **Lin SH** 2005 Thyrotoxic periodic paralysis. *Mayo Clin Proc* 80:99–105 (Review) Abstract
28. **Fisher J** 1982 Thyrotoxic periodic paralysis with ventricular fibrillation. *Arch Intern Med* 142:1362–1364 Abstract
29. **Loh KC, Pinheiro L, Ng KS** 2005 Thyrotoxic period paralysis complicated by near-fatal ventricular arrhythmias. *Singapore Med J* 46:88–89 Abstract
30. **Randall BB** 1992 Fatal hypokalemic thyrotoxic periodic paralysis presenting as the sudden, unexplained death of a Cambodian refugee. *Am J Forensic Med Pathol* 13:204–206 Abstract
31. **Manoukian MA, Foote JA, Crapo LM** 1999 Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. *Arch Intern Med* 159:601–606 Abstract

32. **Norris KC, Levine B, Ganesan K** 1996 Case report: thyrotoxic periodic paralysis associated with hypokalemia and hypophosphatemia. *Am J Kidney Dis* 28:272–273 Abstract
33. **Ryzen E, Servis KL, Rude RK** 1990 Effect of intravenous epinephrine on serum magnesium and free intracellular red blood cell magnesium concentrations measured by nuclear magnetic resonance. *J Am Coll Nutr* 9:114–119 Abstract
34. **Tengan CH, Antunes AC, Gabbai AA, Manzano GM** 2004 The exercise test as a monitor of disease status in hypokalaemic periodic paralysis. *J Neurol Neurosurg Psychiatry* 75:497–499 Abstract
35. **Hsu YJ, Lin YF, Chau T, Liou JT, Kuo SW, Lin SH** 2003 Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. *Am J Med Sci* 326:128–132 Abstract
36. **Khan FA, Baron DN** 1987 Ion flux and Na⁺, K⁺-ATPase activity of erythrocytes and leucocytes in thyroid disease. *Clin Sci* 72:171–179 Abstract
37. **Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R** 1991 *In vivo* and *in vitro* sodium pump activity in subjects with thyrotoxic periodic paralysis. *Br Med J* 303:1096–1099
38. **Lam KSL, Yeung RTT, Benson EA, Wang C** 1989 Erythrocyte sodium-potassium pump in thyrotoxic periodic paralysis. *Aust NZ J Med* 19:6–10
39. **Lo CS, Edelman IS** 1976 Effect of triiodothyronine on the synthesis and degradation of renal cortical Na⁺ K⁺ adenosine triphosphatase. *J Biol Chem* 251:7834–7840 Abstract
40. **Curfman GD, Crowley TJ, Smith TW** 1977 Thyroid-induced alterations in myocardial sodium-potassium-activated adenosine triphosphatase, monovalent cation active transport, and cardiac glycoside binding. *J Clin Invest* 59: 586–590 Abstract
41. **Lin MH, Akera T** 1978 Increased Na⁺, K⁺-ATPase concentrations in various tissues of rats caused by thyroid hormone treatment. *J Biol Chem* 253:723–726 Abstract
42. **Liberman UA, Asano Y, Lo CS, Edelman IS** 1979 Relationship between Na⁺-dependent respiration and Na⁺ K⁺-adenosine triphosphatase activity in the action of thyroid hormone on rat jejunal mucosa. *Biophys J* 27:127–144 Abstract
43. **Blanco G, Mercer RW** 1998 Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. *Am J Physiol* 275:F633–F650 Abstract
44. **Pestov NB, Adams G, Shakhparonov MI, Modyanov NN** 1999 Identification of a novel gene of the X, K-ATPase β-subunit family that is predominantly expressed in skeletal and heart muscles. *FEBS Lett* 275:243–248 Abstract
45. **Chaudhury S, Ismail-Beigi F, Gick GG, Lavenson R, Edelman IS** 1987 Effect of thyroid hormone on the abundance of Na, K-adenosine triphosphatase α-subunit messenger ribonucleic acid. *Mol Endocrinol* 1:83–89 Abstract
46. **Desai-Yajinik V, Zeng J, Omorik, Sherman J, Morimoto T** 1995 The effect of thyroid hormone treatment on the gene expression and enzyme activity of rat liver sodium potassium dependent adenosine triphosphatase. *Endocrinology* 136:629–639 Abstract
47. **Layzer RB** 1982 Periodic paralysis and the sodium-potassium pump. *Ann Neurol* 11:547–552 Abstract
48. **Shishiba Y, Shimuzu T, Saito T, Shizuma K** 1972 Elevated immunoreactive insulin concentration during spontaneous attacks in thyrotoxic periodic paralysis. *Metabolism* 21:285–290 Citation

49. **Lee KO, Taylor EA, Oh VMS, Cheah JS, Aw SE** 1991 Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. *Lancet* 337:1063–1064 Abstract
50. **Hundal HS, Marette A, Mitsumoto Y, Ramlal T, Blostein R, Klip A** 1992 Insulin induces translocation of the $\alpha 2$ and $\beta 1$ subunits of the Na⁺/K⁺-ATPase from intracellular compartments to the plasma membrane in mammalian skeletal muscle. *J Biol Chem* 267:5040–5043 Abstract
51. **Hawkins BR, Ma JTC, Lam KSL, Wang CCL, Yeung RTT** 1985 Association of HLA antigens with thyrotoxic Graves' disease and periodic paralysis in Hong Kong Chinese. *Clin Endocrinol (Oxf)* 23:245–252 Abstract
52. **Yeo PPB, Chan SH, Lui KF, Wu GB, Lim P, Cheah JS** 1978 HLA and thyrotoxic periodic paralysis. *Br Med J* 2:930 Citation
53. **Tamai H, Tanaaha K, Komaki G, Matsubayashi S, Hirota Y, Mori K, Kuma**

2495

- K, Kumagai L, Nagataki S** 1987 HLA and thyrotoxic periodic paralysis in Japanese patients. *J Clin Endocrinol Metab* 64:1075–1078 Abstract
54. **Dias de Silva MR, Cerutti JM, Tengan CH, Furuzawa GK, Vieira TCA, Gabbai AA, Maciel RM** 2002 Mutations linked to familial hypokalemic periodic paralysis in the calcium channel $\alpha 1$ subunit gene ($Ca_v 1.1$) are not associated with thyrotoxic hypokalaemic periodic paralysis. *Clin Endocrinol (Oxf)* 56:367–375 Abstract
55. **Kung AWC, Lau KS, Fong GCY, Chan V** 2004 Association of novel single nucleotide polymorphisms in the calcium channel $\alpha 1$ subunit gene ($Ca_v 1.1$) and thyrotoxic periodic paralysis. *J Clin Endocrinol Metab* 89:1340–1345 Full Text
56. **Dias de Silva MR, Cerutti JM, Arnaldi LA, Maciel RM** 2002 A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. *J Clin Endocrinol Metab* 87:4881–4884 Full Text
57. **Lane AH, Markarian K, Braziunene I** 2004 Thyrotoxic periodic paralysis associated with a mutation in the sodium channel gene SCN4A. *J Pediatr Endocrinol Metab* 17:1679–1682 Abstract
58. **Ng WY, Lui KF, Thai AC, Cheah JS** 2004 Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. *Thyroid* 14:187–190 Abstract
59. **Wang W, Jiang L, Ye L, Zhu N, Su T, Guan L, Li X, Ning G** 2006 Mutation screening in Chinese hypokalemic periodic paralysis patients. *Mol Genet Metab* 87:359–363 Abstract
60. **Kung AWC, Lau KS, Cheung WMW, Chan V** 2006 Thyrotoxic periodic paralysis and polymorphisms of sodium-potassium ATPase genes. *Clin Endocrinol (Oxf)* 64:158–161 Abstract
61. **Kim TY, Song JY, Kim WB, Shong YK** 2005 Arg16Gly polymorphism in $\beta 2$ -adrenergic receptor gene is not associated with thyrotoxic periodic paralysis in Korean male patients with Graves' disease. *Clin Endocrinol (Oxf)* 62:585–589 Abstract
62. **Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH** 2004 Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. *Am J Emerg Med* 22:54454–54457
63. **Shayne P, Hart A** 1994 Thyrotoxic periodic paralysis terminated with intravenous propranolol. *Ann Emerg Med* 24:736–740 Abstract
64. **Birkhahn RH, Gaeta TJ, Melniker L** 2000 Thyrotoxic periodic paralysis and intravenous propranolol in the emergency setting. *J Emerg Med* 18:199–202 Abstract

65. **Tassone H, Moulin A, Henderson SO** 2004 The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. *J Emerg Med* 26:157–161 Abstract
66. **Lin SH, Lin YF** 2001 Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. *Am J Kidney Dis* 37:620–623 Full Text
67. **Young RTT, Tse TF** 1974 Thyrotoxic periodic paralysis. Effect of propranolol. *Am J Med* 57:584–590 Citation
68. **Shulkin D, Olson BR, Levey GS** 1989 Thyrotoxic periodic paralysis in a Latin-American taking acetazolamide. *Am J Med Sci* 297:337–338 Abstract
69. **Chen YC, Fang JT, Chang CT, Chou HH** 2001 Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. *Ren Fail* 23:139–142 Abstract

Copyright © 2009 Elsevier Inc. All rights reserved. - www.mdconsult.com

Bookmark URL: [/das/journal/view/0/N/16348846?ja=542376&PAGE=1.html&issn=0021-972X&source=MI](http://das/journal/view/0/N/16348846?ja=542376&PAGE=1.html&issn=0021-972X&source=MI)